Could a lower dose of cyclophosphamide make stem cell transplants less risky?
NCT ID NCT03983850
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can reduce side effects while still preventing the donor cells from attacking the recipient's body. The trial includes 105 people aged 15-65 with blood cancers like leukemia or lymphoma, along with their healthy donors. Participants receive chemotherapy, a stem cell transplant, and the lower-dose drug, with researchers monitoring for complications over five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide
- What this could lead to
- If successful, this could lead to safer stem cell transplants with fewer severe side effects for people with blood cancers.
- What could go wrong
- This is an early-phase trial with only 105 participants, so results may not apply to everyone. Lowering the dose might also reduce its effectiveness in preventing graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug tame graft-versus-host disease when steroids fail?
- Blood cancer patients may need higher antibiotic doses to beat superbugs
- New antibody may offer safer shield against transplant complications
- New drug combo aims to tame immune attack after stem cell transplants
- Could a 30-Day habit shift help blood cancer patients regain control?
- New drug cocktail aims to stop transplant rejection in blood cancer patients